one-hundred and seven patients with acute myelogenous leukemia ( aml ) ranging in age from 15 to 82 yr who were previously untreated , received a 70 day high-dose remission induction regimen consisting of daunorubicin , cytarabine , and thioguanine ( tad ) .
C0023467
acute myelogenous leukemia
C0011015
daunorubicin